Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Summary
This study has two phases: dose escalation and dose expansion. In the dose escalation phase, eligible participants will receive doses of [161 Tb]Tb PSMA I&T on Day 1 of every 6 week Cycle. The dose of [161 Tb]Tb PSMA I&T will vary, and will range between 4.4 GBq to 7.4 GBq. The recommended phase 2 dose (RP2D) of {161 Tb]Tb PSMA I&T will be used in the second phase, dose expansion. [161 Tb]Tb PSMA I&T dose will be reduced by 0.4 GBq for each subsequent cycle (2 to 6).